CONCORD BIOTECH LIMITED (CONCORDBIO) financials

CONCORD BIOTECH LIMITED (CONCORDBIO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Market Cap: ₹14,008Cr.
Current Price: ₹1,339
Stock P/E: 49.3
ROE: 12.6%
ROCE: 17.4%
Book Value: ₹193
Dividend Yield: 0.56%
52W High / Low: ₹1,615/987

In Jun 2026, CONCORD BIOTECH LIMITED (CONCORDBIO) reported sales ₹261 Cr and net profit ₹61 Cr.

Annual TTM: sales ₹1,112 Cr, net profit ₹282 Cr.

Shareholding: Promoters 44.08% (Jun 2026), FIIs 7.53% (Jun 2026), DIIs 9.37% (Jun 2026), Public 39.04% (Jun 2026), No. of Shareholders 83,325% (Jun 2026).

CONCORDBIO quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	310	244	430	204	247	278	326	261
Expenses	174	146	239	143	157	176	204	173
Operating Profit	137	98	190	61	91	102	122	87
OPM %	44%	40%	44%	30%	37%	37%	38%	33%
Other Income	10	15	9	14	13	7	16	13
Interest	0	0	0	0	0	0	0	0
Depreciation	13	13	15	18	18	19	19	18
Profit before tax	133	99	185	57	86	90	118	82
Tax %	26%	25%	23%	26%	26%	25%	24%	26%
Net Profit	99	74	142	43	63	68	90	61
EPS in Rs	9.43	7.08	13.57	4.07	6.01	6.48	8.60	5.85
Raw PDF	—	—	—	—	—	—	—	—

CONCORDBIO profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	512	617	713	853	1,017	1,200	1,055	1,112
Expenses	308	289	439	509	585	693	678	709
Operating Profit	205	328	274	344	432	507	377	402
OPM %	40%	53%	38%	40%	42%	42%	36%	36%
Other Income	31	14	23	35	34	44	49	49
Interest	1	1	6	5	3	1	1	0
Depreciation	21	28	50	54	54	54	74	75
Profit before tax	213	313	241	320	409	496	351	376
Tax %	21%	25%	26%	26%	26%	25%	25%	—
Net Profit	169	235	179	238	305	373	263	282
EPS in Rs	16.15	22.50	17.07	22.76	29.13	35.65	25.17	26.94
Dividend Payout %	22%	0%	3%	30%	30%	25%	30%	—

CONCORDBIO balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10	10	10	10	10	10
Reserves	673	761	990	1,098	1,282	1,515	1,802	2,009
Borrowings	9	52	89	62	32	10	3	1
Other Liabilities	71	118	94	144	191	164	219	216
Total Liabilities	763	941	1,183	1,313	1,515	1,699	2,034	2,237
Fixed Assets	230	240	546	573	593	575	795	786
CWIP	19	141	18	74	173	211	51	79
Investments	229	199	142	74	138	244	335	488
Other Assets	285	361	477	592	611	668	854	883
Total Assets	763	941	1,183	1,313	1,515	1,699	2,034	2,237

CONCORDBIO cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	—	155	167	207	246	265	245	264
Cash from Investing Activity	—	-114	-195	-112	-158	-155	-160	-142
Cash from Financing Activity	—	-43	31	-100	-85	-99	-99	-115
Net Cash Flow	—	-1	3	-4	3	12	-14	7
Free Cash Flow	—	-1	-37	52	101	180	134	169
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	—	100%	74%	98%	92%	85%	70%	96%

CONCORDBIO shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%
FIIs	8.10%	8.33%	9.35%	9.10%	8.03%	7.58%	7.79%	7.53%
DIIs	9.89%	9.65%	9.16%	8.85%	9.55%	9.58%	9.22%	9.37%
Public	37.95%	37.93%	37.41%	37.94%	38.32%	38.75%	38.90%	39.04%
No. of Shareholders	84,298	82,004	81,219	82,045	82,650	81,815	82,249	83,325

CONCORDBIO key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	133	131	105	119	117	125	159	159
Inventory Days	310	312	503	434	430	331	286	483
Days Payable	112	201	152	185	190	150	135	150
Cash Conversion Cycle	331	242	456	368	357	306	310	492
Working Capital Days	177	159	177	163	153	166	193	231
ROCE %	25%	25%	32%	21%	26%	28%	28%	17%

CONCORDBIOUpdated 17 Oct 2026, 23:13

Concord Biotech Limited

CONCORDBIOUpdated 17 Oct 2026, 23:13

Market Cap

₹14,008Cr.

Current Price

₹1,339

High / Low

₹1,615/987

Stock P/E

49.3

ROE12.6%

ROCE17.4%

Book Value₹193

Face Value₹1.00

Dividend Yield0.56%

About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	195	1	123	7	13	65	25	48	4.63
Sep 2023	262	1	143	8	13	113	25	84	8.08
Dec 2023	241	0	135	8	14	100	26	75	7.13
Mar 2024	319	0	185	11	14	131	26	97	9.29
Jun 2024	216	0	135	10	13	78	25	58	5.57
Sep 2024	310	0	174	10	13	133	26	99	9.43
Dec 2024	244	0	146	15	13	99	25	74	7.08
Mar 2025	430	0	239	9	15	185	23	142	13.57
Jun 2025	204	0	143	14	18	57	26	43	4.07
Sep 2025	247	0	157	13	18	86	26	63	6.01
Dec 2025	278	0	176	7	19	90	25	68	6.48
Mar 2026	326	0	204	16	19	118	24	90	8.6
Jun 2026	261	0	173	13	18	82	26	61	5.85

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	239	1	133	11	10	106	34	70	6.93
Mar 2016	276	0	145	8	10	129	33	87	8.61
Mar 2018	340	1	212	36	18	144	30	100	9.61
Mar 2019	436	1	256	17	19	178	33	118	11.32
Mar 2020	512	1	308	31	21	213	21	169	16.15
Mar 2021	617	1	289	14	28	313	25	235	22.5
Mar 2022	713	6	439	23	50	241	26	179	17.07
Mar 2023	853	5	509	35	54	320	26	238	22.76
Mar 2024	1017	3	585	34	54	409	26	305	29.13
Mar 2025	1200	1	693	44	54	496	25	373	35.65
Mar 2026	1055	1	678	49	74	351	25	263	25.17
TTM	1112	0	709	49	75	376	—	282	26.94

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	44.08%
FIIs	7.53%
DIIs	9.37%
Public	39.04%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	44.08%	7.3%	8.12%	40.5%
Dec 2023	44.08%	7%	8.4%	40.52%
Mar 2024	44.08%	6.49%	8.41%	41.03%
Jun 2024	44.08%	7.11%	10.35%	38.46%
Sep 2024	44.08%	8.1%	9.89%	37.95%
Dec 2024	44.08%	8.33%	9.65%	37.93%
Mar 2025	44.08%	9.35%	9.16%	37.41%
Jun 2025	44.08%	9.1%	8.85%	37.94%
Sep 2025	44.08%	8.03%	9.55%	38.32%
Dec 2025	44.08%	7.58%	9.58%	38.75%
Mar 2026	44.08%	7.79%	9.22%	38.9%
Jun 2026	44.08%	7.53%	9.37%	39.04%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	9	268	35	55	367	104	19	42	202	367
Mar 2016	9	329	36	74	448	110	70	43	225	448
Mar 2018	10	585	22	69	685	189	3	151	343	685
Mar 2019	10	673	9	71	763	230	19	229	285	763
Mar 2020	10	761	52	118	941	240	141	199	361	941
Mar 2021	10	990	89	94	1183	546	18	142	477	1183
Mar 2022	10	1098	62	144	1313	573	74	74	592	1313
Mar 2023	10	1282	32	191	1515	593	173	138	611	1515
Mar 2024	10	1515	10	164	1699	575	211	244	668	1699
Mar 2025	10	1802	3	219	2034	795	51	335	854	2034
Mar 2026	10	2009	1	216	2237	786	79	488	883	2237

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	—	—	—	—
Mar 2016	—	—	—	—
Mar 2018	79	-42	-37	0
Mar 2019	—	—	—	—
Mar 2020	155	-114	-43	-1
Mar 2021	167	-195	31	3
Mar 2022	207	-112	-100	-4
Mar 2023	246	-158	-85	3
Mar 2024	265	-155	-99	12
Mar 2025	245	-160	-99	-14
Mar 2026	264	-142	-115	7

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	165	182	236	133	131	105	119	117	125	159	159
Inventory Days	276	321	381	310	312	503	434	430	331	286	483
Days Payable	108	129	210	112	201	152	185	190	150	135	150
Cash Conversion Cycle	334	374	407	331	242	456	368	357	306	310	492
Working Capital Days	195	209	275	177	159	177	163	153	166	193	231
ROCE %	—	37%	—	25%	25%	32%	21%	26%	28%	28%	17%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of CONCORD BIOTECH LIMITED (CONCORDBIO)?

The reported market capitalisation for CONCORD BIOTECH LIMITED (CONCORDBIO) is ₹14,008Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of CONCORDBIO?

The current price shown for CONCORD BIOTECH LIMITED (CONCORDBIO) on Fincrux is ₹1,339 with a 52-week high/low of ₹1,615/987.

What is the P/E ratio of CONCORD BIOTECH LIMITED (CONCORDBIO)?

The stock P/E for CONCORD BIOTECH LIMITED (CONCORDBIO) is 49.3 on Fincrux, with ROE at 12.6% and ROCE at 17.4%.

What were CONCORDBIO latest quarterly results?

For Jun 2026, CONCORD BIOTECH LIMITED (CONCORDBIO) reported sales ₹261 Cr and net profit ₹61 Cr (figures in ₹ crore unless noted).

What are CONCORDBIO annual sales and net profit?

For TTM, CONCORD BIOTECH LIMITED (CONCORDBIO) shows sales of ₹1,112 Cr and net profit of ₹282 Cr on the Fincrux profit & loss statement.

Who owns CONCORD BIOTECH LIMITED (CONCORDBIO)?

Latest shareholding for CONCORD BIOTECH LIMITED (CONCORDBIO) on Fincrux: Promoters 44.08% (Jun 2026), FIIs 7.53% (Jun 2026), DIIs 9.37% (Jun 2026), Public 39.04% (Jun 2026), No. of Shareholders 83,325% (Jun 2026).

Where can I find CONCORD BIOTECH LIMITED (CONCORDBIO) financials?

CONCORD BIOTECH LIMITED (CONCORDBIO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show CONCORDBIO balance sheet and cash flow?

Yes. The CONCORD BIOTECH LIMITED (CONCORDBIO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 23:13